Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 41Unknown 11Recruiting 7Terminated 5Withdrawn 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Thoracic 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 140Leukemia 97Leukemia, Lymphocytic, Chronic, B-Cell 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Hematologic Neoplasms 69Myelodysplastic Syndromes 55Lymphoma 47Lymphoma, Non-Hodgkin 45Lymphoma, B-Cell, Marginal Zone 34Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Lymphoma, Mantle-Cell 33Lymphoma, Follicular 33Burkitt Lymphoma 32Recurrence 28Lymphoma, Large B-Cell, Diffuse 28Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 24Hodgkin Disease 23Neoplasms 22Leukemia, Myelomonocytic, Chronic 22Multiple Myeloma 21Myeloproliferative Disorders 20Waldenstrom Macroglobulinemia 19Lymphoma, Large-Cell, Immunoblastic 19Leukemia, Myeloid, Chronic-Phase 17Congenital Abnormalities 16Primary Myelofibrosis 15Leukemia, Myeloid, Accelerated Phase 14Leukemia, Biphenotypic, Acute 14Mycosis Fungoides 13Lymphoma, T-Cell, Cutaneous 13

Interventions

ibrutinib 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Bronchiolitis Obliterans Syndrome × Other hematologic neoplasm × Clear all
NCT02743546 2025-02-03

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Janssen Research & Development, LLC

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00349518 2016-02-17

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Bristol-Myers Squibb

Phase 2/3 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01988701 2015-03-02

Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease

Ohio State University Comprehensive Cancer Center

Withdrawn
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡